文献速递免疫规划

三价肺炎克雷伯菌疫苗在肺炎小鼠模型中提供保护

Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia.
PubMed 文献 · Vaccine · 2024-08-19

研究构建了融合抗原KP-Ag1(含GlnH、FimA和KPN_00466),与Al(OH)3佐剂配伍免疫小鼠,可激发体液和细胞免疫应答,在肺炎克雷伯菌肺部感染模型中提供保护,并呈现交叉保护效果,KP-Ag1有望成为候选疫苗。

要点

  • KP-Ag1融合抗原与Al(OH)3佐剂免疫小鼠激发强体液和细胞免疫应答。
  • KP-Ag1免疫在小鼠肺部感染模型中提供保护,以IgG1为主的Th2偏向应答。
  • KP-Ag1对不同血清型、耐药和毒力特征的临床分离株显示交叉保护。

核心结论

  • KP-Ag1有望成为肺炎克雷伯菌疫苗开发的候选抗原。

研究设计与样本

  • 研究构建融合抗原KP-Ag1(含GlnH、FimA和KPN_00466),与Al(OH)3佐剂配伍免疫小鼠,并在小鼠肺炎模型和体外实验中评估免疫应答和保护效果。

主要发现

  • KP-Ag1免疫小鼠激发强体液和细胞免疫应答,并在肺炎克雷伯菌肺部感染模型中提供保护。
  • KP-Ag1免疫小鼠血清IgG亚型以IgG1为主,提示主要诱导Th2偏向免疫应答。
  • 调理吞噬杀伤试验提示体液免疫应答在KP-Ag1介导的保护中起关键作用。
  • KP-Ag1在体外促进BMDC活化和成熟。
  • KP-Ag1对血清型、抗生素耐药和毒力特征不同的肺炎克雷伯菌临床分离株显示交叉保护效果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Klebsiella pneumoniae (K. pneumoniae) is an opportunistic pathogen and the major cause of healthcare-associated infections, which are increasingly complicated by the prevalence of highly invasive and hyper-virulent K. pneumoniae strains, necessitating the development of alternative strategies for combatting infections caused by this bacterium. In this study, we successfully constructed a fusion antigen called KP-Ag1, comprising three antigens (GlnH, FimA, and KPN_00466) that were previously identified through reverse vaccinology. Immunization with KP-Ag1 formulated with Al(OH)3 adjuvant elicited robust humoral and cellular immune response in mice, and conferred protective immunity in a murine model of K. pneumoniae lung infection. Further analysis of serum IgG subtypes from mice immunized with KP-Ag1 revealed a predominant IgG1 response, indicating that KP-Ag1 predominantly induces a Th2-biased immune response. Additionally, opsonophagocytic killing assay suggested that humoral immune responses play a pivotal role in mediating protection conferred by KP-Ag1. Moreover, KP-Ag1 was found to promote the activation and maturation of BMDCs in vitro, which is essential for subsequent efficient antigen presentation. More importantly, vaccination with KP-Ag1 demonstrated cross-protective efficacy against clinical isolates of K. pneumoniae varying in serotypes, antibiotic resistance, and virulence profiles. Therefore, KP-Ag1 holds promise as a candidate for K. pneumoniae vaccine development.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chen Z, Gou Q, Yuan Y, et al. Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia. Vaccine. 2024. PMID: 39163713. doi:10.1016/j.vaccine.2024.126217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。